锂盐治疗预防重性抑郁或双相障碍退伍军人重复自杀相关结局:一项随机临床试验
该双盲安慰剂对照随机临床试验在29家退伍军人医疗中心纳入519例近期经历自杀相关事件的双相障碍或重性抑郁退伍军人,比较常规治疗加用缓释碳酸锂与安慰剂。因无效而提前终止,两组重复自杀相关事件无总体差异(HR 1.10,95%CI 0.77-1.55),未观察到非预期安全性问题。
要点
- 在近期有自杀相关事件的双相障碍或重性抑郁退伍军人中,常规治疗加用锂盐未降低重复自杀相关事件发生率(HR 1.10,95%CI 0.77-1.55)。
- 共127例(24.5%)出现自杀相关结局,锂盐组65例、安慰剂组62例;锂盐组死亡1例、安慰剂组3例。
- 试验因无效提前终止,未观察到非预期安全性问题;作者认为仅在现有用药方案中简单加用锂盐不太可能有效预防广泛自杀相关事件。
核心结论
- 在近期经历自杀相关事件的双相障碍或重性抑郁退伍军人中,常规退伍军人事务部精神卫生治疗加用锂盐未降低自杀相关事件发生率(HR 1.10,95%CI 0.77-1.55)。
- 作者认为,仅在现有用药方案中简单加用锂盐不太可能有效预防正在接受心境障碍及大量共病治疗患者的广泛自杀相关事件。
研究设计与样本
- 双盲、安慰剂对照随机临床试验,评估在常规治疗基础上加用锂盐与安慰剂的效应。
- 在29家退伍军人医疗中心筛查2015年7月1日至2019年3月31日期间6个月内有一次自杀行为发作或因预防自杀而住院的退伍军人。
- 共随机519例退伍军人(平均[SD]年龄42.8[12.4]岁;437例[84.2%]男性),锂盐组255例、安慰剂组264例;试验因无效提前终止。
- 干预为缓释碳酸锂起始600 mg/d或安慰剂。
- 主要结局为至首次重复自杀相关事件的时间,包括自杀未遂、被中断的自杀未遂、专门为预防自杀而住院及自杀死亡。
主要发现
- 3个月时平均锂浓度:双相障碍患者0.54 mEq/L,重性抑郁障碍患者0.46 mEq/L。
- 两组重复自杀相关事件无总体差异(HR 1.10;95%CI 0.77-1.55)。
- 共127例参与者(24.5%)出现自杀相关结局:锂盐组65例,安慰剂组62例。
- 锂盐组死亡1例,安慰剂组死亡3例。
- 未观察到非预期安全性问题。
临床怎么用
- 原文未据此给出推荐。
局限性
- 试验因无效提前终止。
- 作者结论指出,仅在现有用药方案中简单加用锂盐不太可能有效预防正在接受心境障碍及大量共病治疗患者的广泛自杀相关事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Suicide and suicide attempts are persistent and increasing public health problems. Observational studies and meta-analyses of randomized clinical trials have suggested that lithium may prevent suicide in patients with bipolar disorder or depression. OBJECTIVE: To assess whether lithium augmentation of usual care reduces the rate of repeated episodes of suicide-related events (repeated suicide attempts, interrupted attempts, hospitalizations to prevent suicide, and deaths from suicide) in participants with bipolar disorder or depression who have survived a recent event. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled randomized clinical trial assessed lithium vs placebo augmentation of usual care in veterans with bipolar disorder or depression who had survived a recent suicide-related event. Veterans at 29 VA medical centers who had an episode of suicidal behavior or an inpatient admission to prevent suicide within 6 months were screened between July 1, 2015, and March 31, 2019. INTERVENTIONS: Participants were randomized to receive extended-release lithium carbonate beginning at 600 mg/d or placebo. MAIN OUTCOMES AND MEASURES: Time to the first repeated suicide-related event, including suicide attempts, interrupted attempts, hospitalizations specifically to prevent suicide, and deaths from suicide. RESULTS: The trial was stopped for futility after 519 veterans (mean [SD] age, 42.8 [12.4] years; 437 [84.2%] male) were randomized: 255 to lithium and 264 to placebo. Mean lithium concentrations at 3 months were 0.54 mEq/L for patients with bipolar disorder and 0.46 mEq/L for patients with major depressive disorder. No overall difference in repeated suicide-related events between treatments was found (hazard ratio, 1.10; 95% CI, 0.77-1.55). No unanticipated safety concerns were observed. A total of 127 participants (24.5%) had suicide-related outcomes: 65 in the lithium group and 62 in the placebo group. One death occurred in the lithium group and 3 in the placebo group. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the addition of lithium to usual Veterans Affairs mental health care did not reduce the incidence of suicide-related events in veterans with major depression or bipolar disorders who experienced a recent suicide event. Therefore, simply adding lithium to existing medication regimens is unlikely to be effective for preventing a broad range of suicide-related events in patients who are actively being treated for mood disorders and substantial comorbidities. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01928446.
引用
- Katz IR, Rogers MP, Lew R, et al. Lithium Treatment in the Prevention of Repeat Suicide-Related Outcomes in Veterans With Major Depression or Bipolar Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022. PMID: 34787653. doi:10.1001/jamapsychiatry.2021.3170
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。